Conference Day One
7:45 am Check-In & Light Breakfast
8:25 am Chair’s Opening Remarks
Creating Easy-to-Scale Projects to Become an Attractive Acquisition Prospect for Investors
8:30 am Navigating Investment Pathways for Startup Companies Within the Nasal Space
Synopsis
- Emphasis on presenting strong preclinical and early clinical data that demonstrate the safety, efficacy, and unique benefits of the intranasal drug, showcasing its potential for market success
- Discussion of the importance of articulating a compelling value proposition that outlines the product’s competitive advantages, potential market impact, and alignment with current healthcare trends
- Insights into building strategic partnerships with industry leaders and highlighting any existing funding or collaborations that enhance credibility
9:00 am Progressing Nasal Products from Development to the Clinic
Synopsis
- Strategies for risk mitigation and timeline progression
- Important considerations for site selection for manufacturing product
9:30 am Roundtable: Exploring Strategies Employed From Starting a Drug Company to Successful Exit
Synopsis
- Overview of key initial steps in building a nasal drug company, including identifying niche markets, developing a unique value proposition, and securing initial funding
- Effective strategies for navigating regulatory pathways and clinical trials specific to nasal drug delivery, ensuring compliance, and accelerating product development
- Crafting a strategic exit plan, including identifying potential acquirers, forming partnerships with larger pharmaceutical companies, and positioning the company for maximum valuation at exit
10:00 am Speed Networking
Synopsis
This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get face-to-face time with many of the nasal formulation and delivery experts to establish meaningful business relationships.
10:30 am Morning Break & Networking
11:00 am Keep It Simple Stupid: Making Intranasal Biologic Drugs for Population Scale Access
Synopsis
- GMP scalability and COGS once made intranasal biologics impossible
- New technology makes this feasible today, unlocking key advantages in development costs, commercial viability, and equitable access
- How to think about optimally balancing the tradeoffs between safety, purity, and developability
11:30 am Paving the Fast Track to Intranasal Innovation
Synopsis
- Nasal Market Evolution – Commercial growth factors and pipeline of development trends in CNS
- Development pathway- Formulation device combination for intranasal delivery- challenges, risks, and options to consider
- Scientific Progress – Direct delivery to the CNS and recent research into nose to brain
12:00 pm Lunch & Networking
Increasing Drug Bioavailability in Target Regions to Maximize Drug Utility
1:00 pm Enhancing Bioavailability of Nasal Drugs to Maximise Drug Retention in the Brain
Synopsis
- Discussion of innovative formulation approaches designed to facilitate direct drug transport to the brain while minimizing systemic absorption into the bloodstream
- Examination of techniques to optimize the intranasal delivery route, including device design and administration protocols, to enhance localized drug retention
- Ways to assess the distribution of drugs in the brain versus systemic circulation, guiding formulation adjustments to improve overall bioavailability and therapeutic efficacy
1:30 pm Can Guided Stream Technology Unlock Targeted Nose-to-Brain Drug Delivery?
Synopsis
- An effective nose-to-brain delivery of therapeutics via the olfactory pathway implies a targeted delivery of the formulation to the olfactory area.
- Reviewing the performance of available devices illustrates the difficulties in achieving targeted deposition. In addition, there are no standards for in vitro characterization tools and methods to assess the nasal disposition profiles.
- Nemera's “Guided Stream Technology” provides a promising way for a targeted delivery of liquid formulations.
2:00 pm Afternoon Break & Poster Session
Synopsis
Witness some of the latest and greatest research in the nasal drug development & delivery field by drug developers, academics, service providers, and researchers in this spotlight poster session!
3:00 pm Enhancing Bioavailability of Nasal Drugs to Maximize Drug Retention in Systemic Targets
Synopsis
- Increase bioavailability and retention for targeted efficacy
- Explore pathways to enhance systemic absorption
- Strategies to reduce nasal clearance for sustained drug impact
3:30 pm Bridging Pre-Clinical & Early Human Studies With Clinical Design
Synopsis
- Case-study led insights on current clinical development program
- Design of clinical trials and how this is linked back to delivery
- Ways to optimize these methods
4:00 pm Chair’s Closing Remarks
4:10 pm Drinks Reception Hosted by Silgan Dispensing
Synopsis
Grab a Glass! Join our dedicated drinks reception to further connect and network with like-minded experts!